* It involved 50 patients divided into two groups: those with resectable tumors and those with unresectable tumors, showing a higher prevalence in males aged 41-60.
* The findings suggest that borderline unresectable patients can benefit from induction chemotherapy to shrink tumors, allowing for possible surgical intervention and improved chances of recovery.